muraglitazar has been researched along with metformin in 3 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (metformin) | Trials (metformin) | Recent Studies (post-2010) (metformin) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 17,793 | 3,176 | 12,526 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Fiedorek, FT; Ledeine, JM; Rubin, CJ | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
1 review(s) available for muraglitazar and metformin
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
2 trial(s) available for muraglitazar and metformin
| Article | Year |
|---|---|
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2008 |